Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_assertion description "[Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_assertion evidence source_evidence_literature NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_assertion SIO_000772 19151770 NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_assertion wasDerivedFrom befree-20140225 NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_assertion wasGeneratedBy ECO_0000203 NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.
- befree-20140225 importedOn "2014-02-25" NP894500.RA7F1ziK43rE8IK9W-tb8qGbCceNJkEIXuXL5MVXYcND0130_provenance.